


# endoret® (prgf®)

Endogenous Regenerative Technology

## EFFICACY & SAFETY IN HAIR GROWTH (ANDROGENIC ALOPECIA)

ENDORET® (PRGF®) PROMOTES IMPROVED  
ANAGEN/TELOGEN RESULTS THAN  
TOPICAL MINOXIDIL

**FIG 1.** Anagen (active growing phase) follicle number achieved a  $6.9\% \pm 0.4$  improvement after Endoret (PRGF) treatment, while  $4.7\% \pm 0.5$  was achieved after minoxidil application. Moreover a  $5.7\% \pm 0.3$  improvement in telogen (active falling phase) follicle decrease after Endoret (PRGF) treatment was achieved, while only a  $2.6\% \pm 0.5$  was achieved using minoxidil therapy.



**ENDORET® (PRGF®) IMPROVES 1.5 TIMES ANAGEN HAIR GROWTH  
AND DECREASES 2.2 TIMES TELOGEN HAIR GROWTH  
OVER TREATMENT WITH MINOXIDIL**

# ABSTRACT

---

**M. R. Navarro, M. Asín, M. A. Martínez, A. M. Martínez, C. Molina, L. Moscoso, A. Pino, G. Orive & E. Anitua**

Efficacy of Endoret for androgenic alopecia (AGA) compared to topical minoxidil  
Eur J Plast Surg 2016 June;39(3):173-180

## PURPOSES

**The purpose of the present study was to evaluate and compare the efficacy and safety of plasma rich in growth factors (PRGFs) versus topical minoxidil treatment in AGA affected patients.**

## METHODS

Following a retrospective case control design, 379 patients treated with either PRGF or minoxidil were included in this study. Diagnostic trichograms at baseline and 4 months after treatment were performed with the aim of analyzing the anagen/telogen hair change improvement.

## RESULTS

PRGF-treated patients showed higher anagen hair increase improvement compared to minoxidil-treated ones ( $6.9 \pm 0.4$  and  $4.6 \pm 0.5$  %, respectively) ( $p < 0.05$ ). Telogen hair decrease improvement was also higher in PRGF group ( $5.7 \pm 0.3$  and  $2.6 \pm 0.5$  %, respectively) ( $p < 0.05$ ). Global photographs showed an overall volume and quality hair improvement for both treatments. No adverse effects were reported.

## CONCLUSIONS

This retrospective study shows that PRGF is a safe and effective treatment for AGA and evidences that PRGF exerts improved anagen/telogen results than topical minoxidil.

## LEVEL OF EVIDENCE

Level IV, therapeutic study.